---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000104"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:18:27.359520+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025

## Summary
- Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.
- Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.
- Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.
- CFO Blaine Davis continues as both principal financial officer and principal accounting officer.
- Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete.

## SEC filing metadata
- accession: 0001453687-25-000104
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/0001453687-25-000104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/rnac-20251002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000104
- JSON: https://secwatch.observer/filing/0001453687-25-000104.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.